Innovation beyond borders

We are the world’s biggest public network for international cooperation in R&D and innovation, present in over 45 countries.

Eureka in your country

What we do for you

Provide access to public funding

As the national funding body in your country, we give you access to public funding for your R&D projects.
Drive international collaboration

We can help you find international partners, build your ideal project consortium and choose the best programme.
Boost expansion into new markets

We will support you as you access new markets by providing tools and advice for expansion.
Offer personalised advice

The Eureka national project coordinator (NPC) in your country can advise, support and guide you from the development of your project idea to its commercialisation.

Why Eureka?

Good news for deep-tech SMEs: Eureka signs open innovation agreement with major corporates

New relationship will offer opportunities for SMEs to establish partnerships with corporate venturing teams, in cooperation with the EU-funded InvestHorizon1 programme.

Read more
Eurostars-3: A key instrument for Horizon Europe
Why Eurostars is an essential component of Horizon Europe.

Insights
1. Horizon Europe emphasises the need to reinforce support to SMEs for the research and development of emerging and breakthrough innovations. There is a need for policies directly targeting SMEs and that aim to close the innovation gap in the European Union.
2. The Innovative SMEs Partnership delivers a unique 1:3 leverage cash effect on EU funds. The total leverage effect, including private and public funds, is 1:7.
3. The new strategy for the European Research Area (ERA) recommends member countries allocate a target of 5% R&D expenditure to international funding programmes[1].
4. The final allocation of funds from Horizon Europe to the Innovative SMEs Partnership should be proportionate to the budgetary situation of the Framework Programme.
5. Eureka considers an allocation of 300 M€ to the Innovative SMEs Partnership to be an optimal balance between diversity of European interests and sharing the burden of budget cuts, while ensuring the viability of a funding programme with a proven track record for creating jobs and growth.
Read more
New immune risk drug test opens up pharma sector

A Eurostars project partnership has blossomed into an innovative startup, which aims to make the pre-clinical testing of drugs for immune response risks affordable and straightforward. This could help open up the pharmaceutical market to smaller European pharma firms, and ensure that medicines that reach the market do not have unexpected side effects.

Read more